Developments in Anesthesia in the Past 30 Years 

The past 30 years have brought major developments in anesthesia. Though the discovery of new drug classes has proven elusive, researchers have found success in the refinement of existing pharmacological agents, the development of a new neuromuscular blockade reversal agent, and the adoption of multiple new techniques with substantial benefits for perioperative safety.  

From a pharmacological standpoint, progress in recent decades has centered on the refinement of existing drugs, with much less innovation compared to earlier periods in anesthesia research. An analysis of publication trends in anesthetic drugs from 1984 to 2013 found that no new anesthetic introduced during this period produced changes in scientometric indices indicative of real progress¹. There has also been a broader decline in novel drug approvals, with the number of new anesthetics approved by the U.S. Food and Drug Administration falling sharply after 1985².  

Within this context, one pharmacological development stands apart: remifentanil. An ultra-short-acting opioid metabolized by nonspecific plasma and tissue esterases rather than hepatic or renal pathways, remifentanil enabled a degree of moment-to-moment analgesic titration previously unavailable³, and its use in combination with propofol has been instrumental in total intravenous anesthesia (TIVA). 

Perhaps the most consequential pharmacological innovation of the past three decades has been sugammadex. Prior to its development, reversal of neuromuscular blockade relied on acetylcholinesterase inhibitors such as neostigmine, which are nonspecific, less effective at deep levels of block, and associated with muscarinic side effects. Sugammadex, a modified gamma-cyclodextrin, works through a fundamentally different mechanism: it encapsulates rocuronium molecules in a tightly bound complex, rapidly reducing free plasma concentrations and reversing blockade quickly regardless of block depth⁴. The first human study demonstrated recovery to a train-of-four ratio of 0.9 within two minutes following an 8 mg/kg dose administered during profound block⁴.  

Beyond pharmacology, advances in monitoring and technique have reshaped daily practice. The bispectral index (BIS), derived from the electroencephalogram, provided anesthesiologists with an objective, continuous measure of anesthetic depth. A landmark 1994 study by Kearse et al. demonstrated that BIS correlated significantly with patient movement in response to skin incision during propofol-nitrous oxide anesthesia, outperforming conventional EEG power spectrum parameters⁵. 

Additionally, in a 2007 prospective randomized controlled trial, the transversus abdominis plane (TAP) block, a regional technique providing analgesia for the abdominal wall, reduced 24-hour intravenous morphine requirements by more than 70% following large bowel resection⁶. Finally, point-of-care gastric ultrasound emerged as a practical noninvasive tool for aspiration risk assessment^7,8 that has become increasingly utilized, especially in current practice as clinicians adapt to the growing use of GLP-1 drugs that affect digestion.  

Although foundational drug classes have remained dominant in the field of anesthesia over the past 30 years, developments in drugs and techniques have enabled greater technical precision and increased patient safety. The absence of truly novel anesthetic mechanisms underscores an ongoing challenge for the discipline, even as techniques such as TIVA, regional neuraxial blocks, and point-of-care ultrasound continue to advance patient care in substantive ways. 

References 

1. Vlassakov, K. V. & Kissin, I. Scientometrics of anesthetic drugs and their techniques of administration, 1984–2013. Drug Des. Devel. Ther. 8, 2463–2473 (2014). https://doi.org/10.2147/DDDT.S73862 

2. Kissin, I. High-impact clinical studies that fomented new developments in anesthesia: history of achievements, 1966–2015. Drug Des. Devel. Ther. 15, 2495–2505 (2021). https://doi.org/10.2147/DDDT.S316636 

3. Rosow, C. E. An Overview of Remifentanil. Anesth. Analg. 89, 1 (1999). https://journals.lww.com/anesthesia-analgesia/fulltext/1999/10001/an_overview_of_remifentanil.1.aspx 

4. Gijsenbergh, F., Ramael, S., Houwing, N. & van Iersel, T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 103, 695–703 (2005). https://doi.org/10.1097/00000542-200510000-00007 

5. Kearse, L. A. Jr. et al. Bispectral analysis of the electroencephalogram correlates with patient movement to skin incision during propofol/nitrous oxide anesthesia. Anesthesiology 81, 1365–1370 (1994). https://doi.org/10.1097/00000542-199412000-00010 

6. McDonnell, J. G. et al. The analgesic efficacy of transversus abdominis plane block after abdominal surgery: a prospective randomized controlled trial. Anesth. Analg. 104, 193–197 (2007). https://doi.org/10.1213/01.ane.0000250223.49963.0f 

7. Perlas, A., Chan, V. W. S., Lupu, C. M., Mitsakakis, N. & Hanbidge, A. Ultrasound assessment of gastric content and volume. Anesthesiology 111, 82–89 (2009). https://doi.org/10.1097/ALN.0b013e3181a97530 

8. Kruisselbrink, R. et al. Diagnostic accuracy of point-of-care gastric ultrasound. Anesth. Analg. 128, 89–95 (2019). https://doi.org/10.1213/ANE.0000000000003372